Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children

Summary

This is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical delgocitinib cream applied to pediatric subjects (2-17 years) and adult subjects (18 years and above) with atopic dermatitis.

Timeline

Start

2019-02-20

Primary completion

2021-10-29

Completion

2021-10-29

Publications

• Gooderham M, Bunick CG, Yu J, Maslin D, Schneider SKR, Osterdal ML, Sohoel A, Madsen DE, Eichenfield LF. Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial. Dermatol Ther (Heidelb). 2026 Jul;16(7):3275-3283. doi: 10.1007/s13555-026-01767-1. Epub 2026 May 17.

Drugs

Indications